Interaction between quinupristin/dalfopristin and cyclosporine

被引:16
作者
Stamatakis, MK [1 ]
Richards, JG [1 ]
机构
[1] W VIRGINIA UNIV,DEPT MED,NEPHROL SECT,MORGANTOWN,WV 26506
关键词
cyclosporine; quinupristin/dalfopristin; drug interactions;
D O I
10.1177/106002809703100509
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To describe a case of a drug interaction between cyclosporine and quinupristin/dalfopristin (QND). CASE SUMMARY: A patient who had undergone a kidney transplant and was receiving chronic cyclosporine therapy was treated with the investigational streptogramin antibiotic QND. Baseline trough cyclosporine concentrations ranged from 80 to 105 ng/mL. Two and 3 days after initiation of QND therapy, trough cyclosporine concentrations increased to 261 and 291 ng/mL, respectively. Following discontinuation of QND, the cyclosporine blood concentration decreased and the dosage was subsequently increased to the previous regimen. DISCUSSION: A patient's cyclosporine blood concentration tripled 3 days after initiating therapy with QND,A one-third reduction in the cyclosporine dosage was required. QND was the most likely cause for the change in cyclosporine blood concentrations, probably due to inhibition of cyclosporine metabolism. This represents the first published case of an interaction between cyclosporine and QND. CONCLUSIONS: Frequent monitoring of cyclosporine concentrations with attention to the need for dosage modification is recommended when initiating or discontinuing QND therapy.
引用
收藏
页码:576 / 578
页数:3
相关论文
共 9 条
[1]   ASSESSMENT OF LIVER METABOLIC FUNCTION - CLINICAL IMPLICATIONS [J].
BROCKMOLLER, J ;
ROOTS, I .
CLINICAL PHARMACOKINETICS, 1994, 27 (03) :216-248
[2]   INVITRO ACTIVITY OF RP59500, AN INJECTABLE STREPTOGRAMIN ANTIBIOTIC, AGAINST VANCOMYCIN-RESISTANT GRAM-POSITIVE ORGANISMS [J].
COLLINS, LA ;
MALANOSKI, GJ ;
ELIOPOULOS, GM ;
WENNERSTEIN, CB ;
FERRARO, MJ ;
MOELLERING, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :598-601
[3]   IN-VITRO ANTIMICROBIAL SUSCEPTIBILITY OF GLYCOPEPTIDE-RESISTANT ENTEROCOCCI [J].
FREEMAN, C ;
ROBINSON, A ;
COOPER, B ;
MAZENSSULLIVAN, M ;
QUINTILIANI, R ;
NIGHTINGALE, C .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 21 (01) :47-50
[4]  
GAGNADOUX MF, 1987, PRESSE MED, V16, P1761
[5]   Quinupristin-dalfopristin (RP 59500): An injectable streptogramin combination [J].
Griswold, MW ;
Lomaestro, BM ;
Briceland, LL .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (17) :2045-2053
[6]  
HERBRECHT R, 1990, REV INFECT DIS, V12, P371
[7]   IN-VITRO ACTIVITY OF RP-59500 (QUINUPRISTIN DALFOPRISTIN) AGAINST ANTIBIOTIC-RESISTANT STRAINS OF STREPTOCOCCUS-PNEUMONIAE AND ENTEROCOCCI [J].
JOHNSON, CC ;
SLAVOSKI, L ;
SCHWARTZ, M ;
MAY, P ;
PITSAKIS, PG ;
SHUR, AL ;
LEVISON, ME .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 21 (03) :169-173
[8]   INVITRO ACTIVITY OF RP 59500, A SEMISYNTHETIC STREPTOGRAMIN, AGAINST STAPHYLOCOCCI AND STREPTOCOCCI [J].
PECHERE, JC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 :15-18
[9]  
YEE GC, 1990, TRANSPLANT P, V22, P1203